The contemplated transaction remains subject to due diligence, definitive agreements, regulatory approvals and Nasdaq listing requirements; no change to ABL S.A.’s control over ABL Diagnostics at this ...

ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger The contemplated transaction remains subject to due ...

Behringer is no stranger to remaking classic synthesizers and selling them at much cheaper price points. However, this latest release may just take the budget-friendly cake. The company just ...

Energy and marine consultancy ABL has secured new five-year contracts with long-term client Woodside Energy that expands its existing workscope outside of Australia. ABL has been awarded a global ...

Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific antibodies. ABL Bio will receive an upfront payment and potential milestone ...

South Korea’s newest billionaire is Lee Sang-hoon, founder of Seoul-based ABL Bio, after it struck a $2.6 billion licensing and joint research deal with Eli Lilly for its bispecific antibody ...

Cedric Henley, chief risk officer of specialty finance at SLR Capital Partners, switched his career path to finance from law when he was an undergraduate at the University of Southern California.

The companies have yet to disclose how many programs they plan to collaborate on or what indications they will prioritize. For the second time in as many weeks, Eli Lilly is taking out its checkbook ...

Behringer has announced the release of BQ-10, an analogue semi-modular sequencer based on the classic Korg SQ-10. Having first teased BQ-10 all the way back in 2023, Behringer has made the instrument ...

Abacus Global Management Inc (NASDAQ:ABL) reported a record quarter with a 124% year-over-year increase in total revenue, reaching $63 million. The company achieved its 10th consecutive quarter of ...

Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into the clinic. ABL, a Korean biotech that is partnered with companies ...